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1, IN’IXOIXJCTION 
A I’nmily af rnuscorinir: rcccptors mdiatcs n varicr~ 
of dholin~rgic off’ccts in the nervous system, hci\rt, 
snzoott~ nlusck, and glands, Molecular cloning studios 
hnvs idcntificd five miiscnrinic rcccptor gcncs (ml-m5) 
[l-J], and each mKNA has been f’ound to bc trnnscrib- 
cd sckctivcly in certain brain regions ant1 other tissues 
[5-‘91. Investigations of the ml-m5 gene products, 
howcvcr, have been limit4 by the unavailability of 
rcagcnts sclcctivc for c~h of the highly related pro- 
tcins. Even the most ‘specific’ muscnrinic drugs, such as 
pircnzipinc, arc not highly sclcctivc (i.e. have grcatcr 
than IO-fold diffcrcnccs in nffinitics) for the cloned 
rcccptor subtypes [8,9]. To bcttcr understand the 
biology of the muscarinic receptor family, we describe 
a molecular/immunological strategy for discriminating 
the related proteins. The third cytoplasmic (i3) loops of 
the muscarinic receptor subtypes are well suited for 
raising subtype-specific antisera since they are 
divergent, large (157403 amino acids), and hydrophilic 
[2,10], with the only homologies between subtypes at 
the extreme ends of the loops Ill]. Recombinant 
basterial expression plasmids were constructed that en- 
code the unique regions of the i3 loops of the five 
human muscarinic receptors. The i3 fusion proteins 
were expressed inE. co/i and used to produce rabbit an- 
tiscril. WC show that the antisera re highly specific for 
the fusion proteins and each cloned rcccptor subtype. 
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Portions ofthc i3 rcgioris of lhc ml-5 rmptor gcncs wcrc sobclon~ 
cd into ~11~ haL’tCrial zaprcssion vectors pET3a or pET3b [ 121 as shown 
In ‘Tablo I. Ilccn~~~c Of difficult& cxprcssing lhc m3i3 fusion pruicin, 
thi3 lO0p \Yi\s illSO s~lbclolWcl iirk) pGl’,X27’ [ 13). tICOX- 
yoligonurlcnridc prirncrs (4%51 bases) wcrc used 10 amplify, by rhc 
polymcrilsc hin rc;lctioa (PCR), the DNA regions cncociing most of 
rhc i3 loops but excluding the conscrvcd regions at the N- nnd C- 
terminal ends, Restriction sites for UarnHl, &Ill, or EwR1 were in- 
corporntcd into the primers a~ both ends of the DNA fmgmcnts. III 
addition, stop codons in all three reading frtamcs wcrc placed iii the 
downstream primer to insure that no additional amino acids were 
translated. Thu sequences of the dcoxyoligonuclcotidc primers wcrc: 
ml (S’), TG’T CCA GGA TCC GAG KG CC/a GGC AAA GGG 
GGT GGC AGC AGC AGC ACC; ml (3’), CGT AGC AGA TCT 
TAC TAC TTC CGC TTG GCC AGC TGC TCC l-l-l- CCA CGG 
GG; m2 (50, CGA TCG AGA TCT GTT GCC AAC CAA GAC 
CCC GTT TCT CCA AGT CT0 GTA C; m2 (3’), CGT AGC AGA 
TCT TAT CAC TGC ‘l-l?- TCA TCT CCA TTC TGA CCT GAA 
GAC CC; m3 (S’), AGG TCC GGA TCC AAC AGG AGO AAG 
TAT GGC CGC TGC CAC TTC TGG TTC ACA; m3 (3’), AGG 
TCC GAA TTC AAG TGA TCT GAC TTC TGG l-CT TCA GAG 
CAA ACC TC; m4 (S’), AGO TCC GGA TCC GA4 GGA GAA 
GAA AGC CAA GAC GCT GGC CTT CCT CAA GA; m4 (3’), 
CGT AGC AGA TCT TAC TAG CGC ACC TGG TTG CGA GCG 
ATG CTG GCG A.AC TT; m5 (5’), AGO TCC GGA TCC AAA 
GCT GAG AAG AGA AAG CCA GCT CAT AGO GCT CTG TT; 
m5 (3’), CGT AGC AGA TCT TAC TAC ATT TGA TOG CTG 
GGG TTG GGA ?TG AGO CCT TT. PCR amplification of the 
DNA, isolation and restriction digestion of the PCR fragments, and 
subcloning were all pcrforrrcd using standard procedures [14]. The i3 
fragments were subcloned into the BemHl site on gHT3a and pET3b, 
and the BarnHI-EcoRI multiple cloning site on pGEXPT. Construc- 
tion of the recombinant plasmids was verified by double-stranded 
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Table 1 
Construction of ml-m5i3 expression plasmids - 
Fusion protein Vector Nucleotides’ Amino acidsb N-terminus sequenceC M,” 
Vector-Linker-[i3 loop...] 
mli3 pET3a 679-1059 126 Me/‘---Arg’*-Gly-[Ser-Glu-Thr...] 13568 
m2i3 pET3a 865-!?@ 135 Mel’---Arg’*-Gly-Ser-[Val-Ala-Asn...l 14369 
m3i3 pGEX2T 907-1438 177 Sj26.__Pro , . ..Gly-[Ser.Asn-Arg...] 19117 
m4i3 pET3b 1500-1955 152 Mef’---Arg’2-Asp-[Pro-Lys-Glu.I .] 16 129 
mSi3 pET3a 710-1278 190 Met’---Afz ‘2-Gl~Ser-ILys-Ala-G!u,.] 21015 
a The nucleotide positions correspond to the designations of the human sequences in GenBank (m2 and m4) and Bonner et al. (with the coding 
sequence starting at base 1 for ml, m3, m5; [3] and unpublished) 
b The number of amino acids encoded in the subcloned regions of tlie i3 Iorvps 
’ Shown are the amino acid sequences at the N-terminus of each fusion protein as encoded by the vector, linker, and i3 portioa of the muscarinic 
genes. The first and last amino acid of the PET fusion protein from gene 10 of bacteriophage T7 are given followed by the linker and initial three 
amino acids of the i3 loops. For the m3i3 fusion, Sj26 is the glutathionc S-transferase 26-kDa protein followed by the first and last amino acid 
of rhe linker and the initial three amino acids of the i3 loop 
“The predicted molecular mass of only the i3 portions of each fusion protein 
dideoxy sequencing. The recombinant pET vectors encode 12 amino with 0.05070 3,3’-diaminobenzidine (Sigma Chemicals) and 0.01% 
acids from bacteriophage T7 gene 10 and one or two amino acids hydrogen peroxide. 
from the linkers fused at the N-terminus of each i3 loop (Table I), The 
m3i3pGEX2T fusion protein consists of the 26-kDa glutathione S- 2.4. ltnmunoprecipitation studies 
transferase @ST, EC 2.5.1.18, from Schistosoma japonicum) at the The cloned ml-m5 receptors used for these experiments were ex- 
N-terminus of the m3i3 loop. The fusicn proteins were expressed in pressed individually in stableCHO-Kl cells lines and the receptor bin- 
strain BL21 (DE3)pLysS using isopropylthiogalactoside (IPTG) to in- ding properties have been previously described [8,9]. The total 
duce transcription as previously described [12]. Culture samples were number of receptors/mg membrane protein for each subtype is : ml, 
analyzed on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel 2518 fmol; m2, 747 fmol; m3, 1831 fmol; m4, 1778 fmol; mS, 954 
electrophoresis (PAGE) stained with Coomassie brilliant blue, The fmol [$,9]. After polytron homogenization in 50 mM sodium 
fusion proteins were recovered in the particulate fraction of lysed phosphate buffer, pH 7.0, containing a protease inhibitor cocktail 
cultures, permitting easy partial purification by washing the pellets (0.2 m&l phenylmethylsulfonyl fluoride, I mM EDT& 1 ,uM 
(spheroplasts) several times with 0.1% Triton X-100 in IO mM Tris, pepstatin A, 1 @g/ml leupeptin, and 10 p&ml soybean trypsin in- 
1 mM EDTA, pH 8.0. After this step, the fusion protein comprised hibitor) membranes were collected by centrifugation at 3OOOOxg for 
greater than 75-80% of the total protein as determined by optical den- 20 min at 4”C, washed, and resuspended in the same buffer to a pro- 
sitometer tracing. Further purification for immunization was achiev- tein concentration of 0.5 mg/ml, and frozen at - 70°C. Muscarinic 
ed by preparative 10% SDS-PAGE, visualization of the proteins by receptors were labeled with either 2.0 nM [‘H]quinuclidinyl benzilate 
immersion of the gel in cold 0.25 M KCI, and excision of the fusion (13H]QN5, 32.9 Ci/mmol, New England Nuclear) for 1 h at 3O’C or 
protein bands. Purity was then assessed by repeating SDS-PAGE. 5 nM [%l]propylbenzilylchohne mustard ([~I-I]PrBCM, 40.0 
Ci/mmol, New England Nuclear) for 30 min at 30°C in the presence 
2.2. Immunization of rabbits 
Two female New Zealand White rabbits were immunized with each 
or absence of l.OpM atropine to determine nonspecific binding. The 
fusion protein. lmmunogens were prepared by trituration of theexcis- 
membranes were washed once in 10 mM Tris buffer, 1.0 KIM EDTA, 
pH 7.4 (TE) and recentrifuged. The [‘HIQNB-labeled receptors were 
ed gel bands in equal volumes of phosphate-buffered saline through solubilized by resuspending the membranes (to 1 .O mg/ml protein) in 
successively smaller bore needles. Gel suspensions were frozen at TB buffer containing 1 .O% digitonin, 0.1% cholic acid as previously 
- 20°C and mixed with an equal volume of Freund’s adjuvant prior described [IS] and [3H]PrBCM-labeled receptors were solubilized 
to immunizarion. Aninals received LO-25 ,ug of protein (in 0.75-1.0 with 0.5% Lubrol. To determine antibody binding, sera were diluted 
ml) per primary injection followed by boosts at three weeks and then 1:50 into 96 well microtiter plate wells containing 15-30 fmol of 
monthly. Venous blood was obtained at 3 and 4 weeks post-boosts, solubilized receptor and incubated for 4 h at 4’C. Goat anti-rabbit 
and the serum was stored at -7O’C with aliquots kept at 4°C for IgG (Pel-Free@ was then added to a final dilution of 1 : 10. After over- 
testing. Since the immune responses of each pair of rabbits were night incubation, plates were centrifuged at 1000x g for 10 min, the 
variable, all studies described below used a single antiserum reactive immunoprecipitates washed twice with TE containing 0.1% digitonin 
with each fusion protein. and 0.01% cholic acid, resuspended in 1% SDS, and radioactivity 
2.3. fmmunoblotting studies 
determined. Controls employing antisera raised against an irrelevant 
Samples of bacterial cultures were electrophoresed on 10% SDS- 
pET fusion protein (consisting of the rat neuronal nicotinic N- 
PAGE, electroblotted onto Immobilon (Whatman) membranes over- 
terminus & subunit) were used to determine nonspecific trapping of 
night at 150 mA constant current. blocked in 5% nonfat dried milk 
receptor in immunoprecipitates and were subtracted from exyerimen- 
for 30 min at room temperature, and incubated overnight at 4°C with 
tal values (average of 13% of the total radioactivity added, n= 10). 
antisera diluted 1: 250. All sera were diluted in Tris-buffered saline 
Concentrations of rabbit and goat sera were optimized for complete 
(TBS), pH 8.0, containing 1% milk and 3% normal goat serum. An- 
precipitation of immunoglobulins, 
tisera were preadsorbed with E. coli lysates 30 min to reduce 
background staining due to natural and induced antibodies reactive 
with bacterial components. After washing several times with TBS 3. RESULTS AND DISCUSSION 
containing 0.1% Tween, the blots were incubated with 1 pg/ml 
affinity-purified horseradish peroxidase-conjugated goat anti-rabbit Bacteria transformed with each of the recombinant 
IgG (Kirkegaard and Perry Laboratories, Inc.) for 2-4 h at room ml-mSi3pET vectors, except m3i3, expressed high 
temperature. Blots were washed and immunoreactivity was visualized levels (5-10 rg/ml) of a single protein (Fig. 1). Since 
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Fig. 1. Bacterial expression of the third cytoplasmic loops of muscarinic receptors ml-m5. 10% SDS-PAGE was performed on samples of E. cob 
cultures transfected with the parental expression vectors pBT or pGEX2T, or the recombinant expression vectors containing the ml:mS third 
cytoplasmic loop (i3) inserts as indicated at the top of each pair of lanes, mli3, m2i3, m4i3, and m5i3 were subcloned into the pET vector and 
m3i3 was subcloned into pGEX2T. Culture samples were taken before (-) and after (+) three hours of induction with 1 .O mM IPTG. Each lane 
was loaded with 200~1 of culture medium, and the pGEX2T samples had a higher density of bacteria (and protein) than the pET cultures. The 
arrowheads mark the positions of the five muscarinic fusion proteins, Molecular weights of the markers (far left lane) are noted on the left. The 
gel was stained with Coomassie brilliant blue. 
these proteins were not expressed prior to induction of the latter compound. Almost complete receptor binding 
transcription with IPTG, they were clearly encoded by was observed with the m3 and rn4 antisera, but signifi- 
the recombinant plasmids, and therefore, represent he cant fractions of the other receptors were not bound. 
i3 loop fusion proteins. Since we were unable to observe. The many possible explanations for the lack o’f com- 
inductinn of an m3i3 fusion protein with the pET vec- plete binding (e.g. dissociation of ligand, deriaturation 
tor, this subtype was inserted into pGEX2T [13], and or degradation of receptors, post-translational. 
abundant fusion protein expression was achieved. The modifications) are presently being investigated. 
fusion proteins all migrated at apparent molecular However, no further binding was observed’tiith fewer 
weights somewhat larger than predicted from their receptors per assay (data not shown), suggesting that 
primary sequences (Table I). antibody concentrations were not limiting. These 
Rabbit antisera were raised against each of the five results demonstrate that the antisera raised against 
purified rnuscarinic receptor i3 loop fusion proteins. On genetically engineered and SDS-denatured i3’ fusion 
immunoblots, each antiserum was highly specific for proteins bind to the undenatured muscarinic receptors, 
the single fusion protein to which it was raised (Fig. 2). and most importantly, are specific for each ,of the 
These studies demonstrated that the i3 loops of ml-m5 ml-m5 subtypes. Moreover, the binding of the an- 
were immunogenic and that under denaturing condi- tibodies to the proposed inner cytoplasmic loops did 
tions the five antisera did not cross-react with other sub- not abolish the ligand binding abilities of the receptors. 
types. These properties should make feasible the immunolo- 
The ability of the antisera to bind individually to the gical detection and quantitation of the native receptor 
five native muscarinic receptors was tested using the im- subtypes in animal tissues. 
munoprecipitation assay. Each antiserum reacted Antibodies specifically reactive -with muscarinic 
highly specifically ,to the appropriate receptor subtype receptors ml-m5 are essential to study the turnover, 
labeled with [3H]QNB (Fig. 3) and with’the irreversible regulation, and localization of receptor subtypes. 
ligand [‘H]PrBCM mustard (data not shown), even at Previous attempts to produce such reagents have ,met 
high concentrations (l/50 final dilution of, antisera). with limited success. For instance, ,monoclona! an- 
The assay with [3H]QNB was more sensitive than with tibodies against brain muscarinic receptors were 
[3H]PrBCM because of more nonspecific binding with developed prior to knowledge of the subtypes [l&16], 
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Fig. 2. Immunoblotting of the muscarimc receptor i3 fusion proteins. Total protein from 150~1 samples of bacterial cultures transfected with either 
mli3pET (lane I), mZi3pET (lane a), m3i3pGEX2T (lane 3), m4i3pET (lane 4), mSi3pET (lane 5). or pGEX2T (lane 6) were analyzed by 10% SDS- 
PAGE and stained with Coomassie brilliant blue as shown in the upper left panel (GEL). In the other panels are shown immunoblots from replicate 
gels reacted with antisera (diluted I : 250) to each of the five muscarinic fusion proteins (indicated under each blot, ml-m5). Antisera were pread- 
sorbed with total protein in lysates from the equivalent of 750 ~1 of bacterial cultures in order to reduce background staining of E. co/i proteins 
(those proteins evident in all lanes of a given blot). Immunoreactivity was localized on the blots using I p&ml affinity-purified horseradish 
peroxirase-conjugated goat anti-rabbit IgG and visualized with 0.05% 3,3 ‘-diaminobenzidine/O.Ol% hydrogen peroxide. Each antiserum showed 
strong reactivity specifIcally with the numerically matched fusion protein. The m3i3 antiserum showed no immunoreactivity with the glutathione 
S-transferase moiety (lane 6), demonstrating that reactivity with the fusion protein antiserum (lane 3) resulted from antibodies reactive with the 
i3 insert. 
and no further studies of their specificity have been develop antibodies against the ml subtype 1181 and 
reported. More recently, rnonoclonal antibodies were more recently, the other subtypes as well [19]. How- 
produced against the heart receptors that appear to be ever, the few epitopes available on the small peptides 
rn%-selective [17]. Synthetic peptides have been used to may limit the diversity and intensity of the antibody 
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ANTISERA 
beled muscarinic receptors ml-m% Cloned human muscarinic receptor subtypes were labeled with 
antisera to the fusion proteins (cu-ml-a-m5), coprecipitated with goat anti-rabbit immunoglobulin, 
‘as determinecl as described in the text, In order to facilitate comparisons between receptors, the or- 
or. The total number of fmol of [‘I-IlQNB per assay was: ml, 33; m2, 14; m3. 31; m4, 14; and m5, 
are the mean of triplicate samples and error bars represent SD. 
response and sometimes their ability to recognize the 
native proteins. This study has demonstrated the 
bacteria] expression of the i3 loops of each of the five 
human muscarinic receptor subtypes and their use for 
production of rabbit antisera. The antisera, characteriz- 
ed by immunoblotting and immunoprecipitation, are 
highly specific for each of the five fusion proteins and 
undenatured receptor subtypes ml -mS, The fusion pro- 
teins and the antisera will be useful for future studies of 
the structure, function, and localization of the family 
of rnuscarinic receptors. 
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